TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04255017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abidol hydrochloride
Description: Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.
Study: NCT04003181

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotics
Description: Ciprofloxacin or Rifaximin for 10 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bile Acid Binder
Description: Cholestyramine or Colesevelam lifelong.
Study: NCT01753830

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durolane
Description: 4.5 mL

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PBS
Description: 4.5 mL
Study: NCT00393068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study: NCT01697852

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indoor residual spraying with bendiocarb
Description: 2 rounds of indoor residual spraying with bendiocarb insecticide, 4 months apart

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LLIN by universal coverage campaign
Description: Long lasting Insecticide treated mosquito net

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LLIN by universal coverage campaign
Description: Long lasting Insecticide treated mosquito net
Study: NCT01322451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259 fumarate
Description: single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259 free base
Description: single oral dose, GLPG0259, 50 mg solid formulation
Study: NCT01081535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac, fentanyl
Description: intravenous PCA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac, fentanyl
Description: intravenous PCA
Study: NCT05638958

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate post-extractive Implant placement
Description: Teeth scheduled for extraction will be used to study the effect of a customized healing abutment. All patients should receive prophylactic antibiotic therapy of 2g of amoxicillin (or clindamycin 600mg if allergic to penicillin) 1 hour before the surgery. Implant placed along the lingual/palatal bone plate and the implant platform should be placed at the level of the buccal bone plate. GUIDOR easy-graft CRYSTAL will be used to fill the defect between implant and buccal bone plate, subsequently, a standard healing abutment or a customized healing abutment will be screw-retained on the implants.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate post-extractive Implant placement
Description: Teeth scheduled for extraction will be used to study the effect of a customized healing abutment. All patients should receive prophylactic antibiotic therapy of 2g of amoxicillin (or clindamycin 600mg if allergic to penicillin) 1 hour before the surgery. Implant placed along the lingual/palatal bone plate and the implant platform should be placed at the level of the buccal bone plate. GUIDOR easy-graft CRYSTAL will be used to fill the defect between implant and buccal bone plate, subsequently, a standard healing abutment or a customized healing abutment will be screw-retained on the implants.
Study: NCT02605356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo, BAY88-8223)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT03864146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Compliance Enhancement Treatment
Description: This is a standardized 15-minute intervention that emphasizes medication adherence as a crucial element to change alcohol use behavior.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Brief Behavioral Compliance Enhancement Treatment
Description: This is a standardized 15-minute intervention that emphasizes medication adherence as a crucial element to change alcohol use behavior.
Study: NCT00845247

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nurse case management
Description: Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
Study: NCT02341651

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Description: Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
Study: NCT02652910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19.CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express CD19-specific CARs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19.CAR-T cells
Description: Retroviral vector-transduced autologous T cells to express CD19-specific CARs
Study: NCT03345446

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac MRI
Description: Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.
Study: NCT03339310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optimizer Smart System with 2-leads
Description: The Optimizer Smart System with 2-leads delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Implanted subjects receive five non-contiguous one-hour periods of CCM signals per day.
Study: NCT04439864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyIDEA
Description: An educational tablet app that is customized to the patient based on the data in the Electronic Health Record.
Study: NCT03272087

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VATS (thoracoscopy)
Description: 50 % of patients will have performed a VATS (video-assisted thoracic surgery) thoracoscopy
Study: NCT03055702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile phone text message reminder
Description: an SMS remind subjects to come for scheduled clinic appointment 24-72 hours before
Study: NCT01763684

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Signature Custom Guides
Description: Signature Custom Guides: Signature Custom Guides are intended to be used as a surgical instrument to assist in the positioning of knee replacement components intraoperatively and in guiding the marking of bone before cutting provided that anatomic landmarks necessary for alignment and positioning of the implant are identifiable on patient imaging scans (preoperative MRI).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Instrumentation
Description: Traditional partial knee arthroplasty without the use of Signature technology.
Study: NCT00131378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutropin AQ growth hormone
Description: Participants will give themselves injections of growth hormone every night for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutropin AQ growth hormone
Description: Participants will give themselves injections of growth hormone every night for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Growth Hormone
Description: Participants will give themselves injections of placebo growth hormone every night for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Growth Hormone
Description: Participants will give themselves injections of placebo growth hormone every night for 6 months.
Study: NCT02131207

Intervention type: PROCEDURE
Intervention: prostate biopsy
Description: Undergo prostate biopsy
Study: NCT00636103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUF2
Description: 0.619g of dried aqueous extract of equal weights of 5 herbs (Astragalus mongholius Bunge, Cordyceps sinensis Sacc., Radix Stemonae, Bulbus Fritillariae Cirrhosae, Radix scutellariae).~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months
Study: NCT02608151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage with oil
Description: Application or not of an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil) during the massage. This oil was chosen due to its composition of essential fatty acids (60%) including: linoleic acid (omega 6,25g 100 g)), linolenic acid (omega 3 5.3g to 100 g) and tocopherol (vitamin E) .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: massage without oil
Study: NCT03823495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week PAP
Description: It is a non-drug intervention, using exercises to reduce elderlies chronic pain.
Study: NCT01950234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH
Description: Acthar gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01289444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAmily CEntered (FACE) ACP
Description: Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care \& when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care \& prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Control
Description: Active Comparator: Three 60 to 90 minute sessions scheduled one week apart. 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition. 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.~3. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides.
Study: NCT00636103

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dark coloured corn starch~The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.~Duration: 6 months
Study: NCT02373748

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioGaming YuGo System
Description: Subjects will perform a customized training program predefined in the BioGaming YuGo system.
Study: NCT03564418

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-Guided Thermocoagulation of Lumbar facet joints
Description: Prone position: Thanks to a high-resolution ultrasound and a 5 MHz curved probe, we will use the ultrasound technique described by Greher et al to reach the target points.~Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol) to observe them using the standard Fluoroscopic method. Wrongly positioned needles will be correctly repositioned and these patients will be excluded from ODI and VAS scale statistics.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that the needle is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy-Guided Thermocoagulation of Lumbar facet joints
Description: Prone position: We will use the standard fluoroscopic method to reach the target points. (maximum three levels, same side). Then, in order to check the correct positioning of the needles, we will inject 1 ml of a solution of contrast medium (omnipaque® 300 mg / ml of Iohexol). The correct location being the superolateral edge of the lateral facet and the diffusion of the contrast material at the level of the medial branch observed thanks to an anteroposterior radioscopic view. Then the location of the needles is confirmed by a lateral radioscopic view.~To ensure the effectiveness of the injury by thermocoagulation, sensory electrical stimulation is performed to confirm that it is close to the posterior ramus (50Hz, 0-3 volts) and another electrical stimulation is performed to confirm that there is no motor stimulation (2Hz, 0-3 volts). After injecting 1 ml of 2% linisol® through the needle, denervation of the facet will be performed with an electrode at 68 ° C for 90 seconds.
Study: NCT04404946

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: phenylephrine infusion
Description: in parturients allocated to the phenylephrine group, a phenylephrine infusion will be started as soon as spinal anesthesia is initiated

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine infusion
Description: in parturients allocated to the norepinephrine group, a norepinephrine infusion will be started as soon as spinal anesthesia is initiated

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo infusion
Description: in parturients allocated to the placebo group, a normal saline infusion will be started as soon as spinal anesthesia is initiated
Study: NCT00523536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator - Nurse Team Intervention
Description: The patient navigator-nurse disease management intervention for treating hypertension and its associated cardiovascular risk factors will use information obtained in earlier phases of the LUCHAR grant: i.e., algorithms, risk factor profiles, and qualitative data from focus groups and interviews. The study will test the effect of this intervention on blood pressure control and utilization of hospital services in adult patients with hypertension.
Study: NCT02054130

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Study: NCT00989612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza investigational vaccine GSK2340274A
Description: Two intramuscular injections on Day 0 and Day 21, respectively
Study: NCT03487328

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacrospinous-Sacrotuberous fixation
Description: Sacrospinous-Sacrotuberous fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacrospinous-Sacrotuberous fixation
Description: Sacrospinous-Sacrotuberous fixation
Study: NCT02054130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9929 70 mg
Description: Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI9929 210 mg
Description: Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Study: NCT04180228

Intervention type: OTHER
Intervention: self-administred questionnaire
Description: On the occasion of a follow-up consultation with referent pediatrician, a self-administred questionnaire is distributed. It will take around ten minutes to the patient and her parents for completing the questionnaire. Questionnaire is anonymous. Participation is free and informed by an information notice. There is a list of items to complete by the patient and her parents. Most of questions are closed-ended. Clinical data are reported : age, level of education, principal disease (SLE or Juvenile arthritis), received treatments. In the questionnaire, it is asked if the patient is vaccinated or not for HPV, and reasons for it.

Intervention type: OTHER
Intervention: self-administred questionnaire
Description: On the occasion of a follow-up consultation with referent pediatrician, a self-administred questionnaire is distributed. It will take around ten minutes to the patient and her parents for completing the questionnaire. Questionnaire is anonymous. Participation is free and informed by an information notice. There is a list of items to complete by the patient and her parents. Most of questions are closed-ended. Clinical data are reported : age, level of education, principal disease (SLE or Juvenile arthritis), received treatments. In the questionnaire, it is asked if the patient is vaccinated or not for HPV, and reasons for it.
Study: NCT03437369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine Oral Tablet
Description: The target dose is 10 to 15 mg / day, administered orally in two doses

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care treatment
Description: The study drug will be compared with the standard of Care treatment
Study: NCT02501902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
Study: NCT03346187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)
Description: Lipitor(Atorvastatin Calcium Trihydrate 20mg/tablet) + Lipidil supra(Fenofibrate 160mg/tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)
Description: Lipitor(Atorvastatin Calcium Trihydrate 20mg/tablet) + Lipidil supra(Fenofibrate 160mg/tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug(CKD-337)
Description: CKD-337(Atorvastatin calcium trihydrate 20mg+choline fenofibrate 178.8mg/capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test drug(CKD-337)
Description: CKD-337(Atorvastatin calcium trihydrate 20mg+choline fenofibrate 178.8mg/capsule)
Study: NCT02869165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen topical cream
Description: Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apricot kernel oil
Description: Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
Study: NCT03618667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC1118
Description: GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycles) up to 6 cycles, or till progression or uncontrolled toxicity.
Study: NCT03673540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT+ application
Description: Smartphone application that comprises electronic self-monitoring of food intake, eating disorder behaviors, and mood and ecological momentary interventions
Study: NCT03688919

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Regulation Intervention
Description: The intervention targets Executive Functioning (EF), Emotion Regulation (ER) and Future Orientation (FO). The intervention will occur through home practice and text based reminders and mobile apps to practice techniques. For EF, youth will use the NBack intervention, a computer-based working memory training game. For ER, participants will engage in relaxation and biofeedback activities by completing activities (e.g., modulating breathing to keep heart rate) while wearing sensors. For FO, participants will envision and describe future events they are looking forward to, using concrete, vivid descriptive language. These descriptions will be audio recorded so that the participant can play back the cues at home at specified times of day (e.g., 7am and 3:30PM).
Study: NCT02671006

Intervention type: OTHER
Intervention: Basophil patterns
Description: The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.

Intervention type: OTHER
Intervention: Basophil patterns
Description: The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.